Clinical trial
Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease
NCT00180037 · Technische Universität Dresden, Other · Completed
Key facts
| NCT number | NCT00180037 |
|---|---|
| Title | Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease |
| Official title | Multicenter, Placebo Controlled, Randomized, Double-Blinded Study: Coenzyme Q10 Nanodispersion Versus Placebo as Symptomatic Treatment in Parkinson's Disease |
| Lead sponsor | Technische Universität Dresden, Other |
| Collaborators | Deutsche Parkinson-Vereinigung e.V. MSE Pharmazeutika GmbH, Bad Homburg |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug |
| Interventions | Coenzyme Q10 Nanodispersion (Nanoquinone), Placebo |
| Enrollment | 132 |
| Start date | Sep 1, 2003 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Sep 16, 2005 |
| Last update posted | Jan 19, 2009 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: